Persistent vulvovaginal candidiasis: systemic treatment with oral fluconazole.

Abstract

52 patients affected by persistent vulvovaginal candidiasis underwent systemic therapy with oral Fluconazole at a dose of 150 mg once a week for 3 weeks. 31 (59.61%) patients were cured at the first control after therapy. Of the remaining 21 patients, 4 (7.69%) were lost at follow-up and 17 (32.69%) underwent a second cycle of systemic therapy with complete recovery confirmed at the further controls. The overall percentage of recoveries was equal to 92.30%. The results suggest that Fluconazole is very effective in mycotic vulvovaginitis with irrelevant side effects.

• Authors: A Frega, G Gallo, F Di Renzi, G Stolfi, P Stentella
• Journal: Clinical and experimental obstetrics & gynecology (Clin Exp Obstet Gynecol) Vol. 21 Issue 4 Pg. 259-62 ( 1994) ISSN: 0390-6663 [Print] Singapore
• PMID: 7994878 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Fluconazole

Topics

• Administration, Oral
• Adolescent
• Adult
• Candidiasis, Vulvovaginal (drug therapy)
• Drug Administration Schedule
• Female
• Fluconazole (therapeutic use)
• Humans
• Middle Aged
• Treatment Outcome